By Mina Lobbous, MD, MPH From: targetedonc.com This study (NCT03501979) investigated the drug combination of tucatinib (Tukysa), trastuzumab (Herceptin), and capecitabine for HER2-positive breast cancer with leptomeningeal metastases (LM). Treatment options for LM are limited, and survival rates are low. The researchers enrolled 17 patients with HER2-positive breast cancer and newly diagnosed LM. All patients received the drug combination in …
Managing HER2+ Early Breast Cancer: A Focus on Target Therapy
From: targetedonc.com New breast cancer diagnoses account for 31% of annual cancer diagnoses among women in the United States.1 Among those diagnoses, HER2 overexpression is observed in 25% to 30% of cases. Historically, HER2-positive (HER2+) breast cancer was considered an aggressive subtype and was associated with a poor prognosis; however, the emergence of HER2-targeted therapies such as trastuzumab has considerably …
Breast Cancer Armamentarium Offers New Options for Patients
By: Sagar Shah, PharmD candidate; and Saro Arakelians, PharmD From: pharmacytimes.com Breast cancer is the second-leading cause of cancer-related death among women in the United States.1 Each year, about 250,000 cases of breast cancer are diagnosed in the United States.2 According to the American Cancer Society, about 276,480 cases of breast cancer will be diagnosed in women in 2020. About …
Key molecule responsible for poor prognosis of breast cancer identified
Source: Hokkaido University From: eurekalert.org Hokkaido University scientists have shown that Interleukin-34 is a prognostic marker and drug target for Triple Negative Breast Cancer. Breast cancer is the most common cancer among women across the world, affecting 28.9% . Depending on the combination of cell receptor molecules present on the surface of the cancer cells, breast cancer is classified into …
First-in-human clinical trial of new targeted therapy drug reports promising responses for multiple cancers
Source: University of Texas M. D. Anderson Cancer Center From: sciencedaily.com A phase I, first-in-human study led by The University of Texas MD Anderson Cancer Center reveals for the first time, an investigational drug that is effective and safe for patients with cancers caused by an alteration in the receptor tyrosine kinase known as RET. The drug appears to be promising …
As Metastatic Brain Tumor Rates Rise, Targeted Therapies Offer a Better Treatment Alternative
Up to 45% of all cancer patients develop brain metastases, tumors that spread to the brain from cancers located elsewhere in the body. As the number of patients affected by metastatic brain tumors grows, targeted treatment options, like the Gamma Knife™ radiosurgery, may offer better tumor control and symptom management. Metastatic brain tumors are some of the most common types …
Updated ASTRO guideline expands pool of suitable candidates for accelerated partial breast irradiation
Guideline update also examines intraoperative radiation treatment options for early-stage breast cancer The American Society for Radiation Oncology (ASTRO) today issued an updated clinical practice statement for accelerated partial breast irradiation (APBI) for early-stage breast cancer. The updated guideline reflects recent evidence that greater numbers of patients can benefit from accelerated treatment and also provides direction for the use of …